



BREAKTHROUGH TECHNOLOGY FOR A BRIGHTER FUTURE

KEY STATISTICS:

(as of June 1, 2017)

Ticker: NASDAQ: ORMP

Market Cap: \$108 mm

Shares Outstanding: 13.2mm

Fully Diluted: 15.7mm

TEAM

Nadav Kidron, Esq., MBA, CEO

Miriam Kidron, PhD, CSO

Yifat Zommer, CPA, MBA, CFO

Josh Hexter, COO, VP Bus. Dev.

Ronald Law, PhD, CSO

SCIENTIFIC ADVISORY BOARD

Roy Eldor, MD, PhD

Ele Ferrannini, MD, PhD

Avram Hershko, MD, PhD

Harold Jacob, MD


Harvey L. Katzeff, MD

Oramed Pharmaceuticals has a proprietary platform technology that allows for the oral delivery of drugs that are presently only available via injection.

- Flagship product oral insulin capsule (ORMD-0801) for treatment of diabetes.
- Successfully completed Phase IIb US FDA trial for type 2 diabetes.
- Experienced management team with many years of pharmaceutical experience.
- Multiple patent families have been granted in numerous countries.

Huge market opportunity: Injectable Insulin > \$20 billion market globally; expected to more than double by 2020.

- Oral Insulin expected to gain significant share of injectable market and may reduce the global economic costs of diabetes, estimated in excess of \$500 billion, by enabling initiation of treatment at an earlier stage.
- \$50 million licensing deal with HTIT for exclusive rights to market ORMD-0801 in Greater China. Oramed will additionally receive 10% royalties on net sales.
- The current cash position should allow the Company to efficiently push forward its clinical development.



ORMD-0801 TYPE 2 DIABETES (T2DM): Will potentially create a new paradigm for the treatment of T2DM by oral delivery of insulin and earlier stage of treatment.

ORMD-0801 TYPE 1 DIABETES (T1DM): In development to replace pre-meal injections for T1DM patients.

ORMD-0901 ORAL GLP-1 ANALOG: Currently available *only* via injection, GLP-1 analog therapies have shown significant impact on glycemic control and preservation of beta cell function in T2DM patients.

COMPANY CONTACT:

Estee Yaari

estee@oramed.com

Tel. Intl. +972-2-566-0001

Tel. US +1844-9-ORAMED

www.oramed.com

FOR UPDATES:



Certain statements contained in this material are forward-looking statements which involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any results performance or achievement expressed or implied by such forward-looking statements. Please refer to the Company's filing with the Security and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in such forward-looking statements.